Kamoun Arwa, Brahim Rimeh Ben, Charfi Aida, Yaich Soumaya, Masmoudi Mondher, Hakim Faiza, Gaddour Lilia, Hmida Mohamed Ben, Makni Hafedh, Mahfoudh Nadia
Immunology department, Hedi Chaker Hospital, University of Sfax, Sfax, Tunisia; Renal Pathology Laboratory, LR19ES11, Hedi Chaker Hospital, University of Sfax, Sfax, Tunisia.
Renal Pathology Laboratory, LR19ES11, Hedi Chaker Hospital, University of Sfax, Sfax, Tunisia.
Hum Immunol. 2025 Mar;86(2):111230. doi: 10.1016/j.humimm.2025.111230. Epub 2025 Jan 9.
HLA matching is critical for successful kidney transplantation. This study aimed to investigate the impact of eplet mismatches and Predicted Indirectly Recognizable HLA Epitopes (PIRCHE-II) scores on the development of de novo donor-specific antibodies (dnDSA) and graft survival in a Tunisian cohort, characterized by a high prevalence of living donors and significant genetic diversity in HLA profiles.
This retrospective study included 112 adult kidney transplant recipients who underwent transplantation between 2012 and 2018. Donor and recipient HLA typing was performed using One Lambda Labtype PCR-SSO and PCR-SSP kits, with high-resolution typing inferred using validated tools and reference datasets. Luminex DSA screening (One Lambda) was conducted at transplantation, during follow-up for graft dysfunction or proteinuria, and at the study's conclusion. Eplet mismatches and PIRCHE-II scores were calculated using EpVix and PIRCHE-II software.
Nineteen patients (17 %) developed dnDSA, predominantly targeting HLA-DQ, with a median detection timeframe of 50 months (range: 11-106 months) post-transplantation. Male donor sex was negatively associated with dnDSA development, while prolonged cold ischemia time was a significant risk factor. Molecular HLA-DQ mismatches and high PIRCHE-II scores were significantly associated with dnDSA. Factors independently associated with reduced death-censored graft survival included history of transfusion after transplantation, allelic DRB1 mismatch, dnDSA development, and elevated PIRCHE-II score.
Our findings highlight the critical role of HLA-DQ compatibility in kidney transplantation and suggest that molecular HLA-DQ matching should be considered in kidney allocation strategies to minimise alloimmune responses and improve long-term graft outcomes.
HLA配型对于肾移植成功至关重要。本研究旨在调查在一个以活体供者高患病率和HLA谱显著遗传多样性为特征的突尼斯队列中,表位错配和预测间接可识别HLA表位(PIRCHE-II)评分对新发供者特异性抗体(dnDSA)产生及移植物存活的影响。
这项回顾性研究纳入了2012年至2018年间接受移植的112例成年肾移植受者。使用One Lambda Labtype PCR-SSO和PCR-SSP试剂盒进行供者和受者HLA分型,并使用经过验证的工具和参考数据集推断高分辨率分型。在移植时、随访期间出现移植物功能障碍或蛋白尿时以及研究结束时进行Luminex DSA筛查(One Lambda)。使用EpVix和PIRCHE-II软件计算表位错配和PIRCHE-II评分。
19例患者(17%)产生了dnDSA,主要针对HLA-DQ,移植后中位检测时间为50个月(范围:11 - 106个月)。男性供者与dnDSA产生呈负相关,而延长的冷缺血时间是一个显著的危险因素。分子HLA-DQ错配和高PIRCHE-II评分与dnDSA显著相关。与死亡删失的移植物存活降低独立相关的因素包括移植后输血史、等位基因DRB1错配、dnDSA产生以及PIRCHE-II评分升高。
我们的研究结果突出了HLA-DQ相容性在肾移植中的关键作用,并表明在肾分配策略中应考虑分子HLA-DQ匹配,以尽量减少同种免疫反应并改善长期移植物结局。